Hard Services System Owner — HVAC & cGMP Leader

Biopharma Careers; Geel; Sur place; EUR 67 000 - 102 000; Plein temps

Résumé du poste

Biopharma Careers is seeking a Hard services system owner specialist in Geel, Belgium. You will be the technical hub for HVAC and utility processes within a cGMP environment, coordinating improvements and ensuring optimal capacity and reliable operation.

As system owner, you will drive investigations, support deviations, and lead project start-ups while shaping budgeted investments and cross-functional collaboration with auditors and stakeholders in a dynamic pharma setting.

Qualifications

• Master’s degree or equivalent in a technical field (electromechanics, chemical technology, industrial engineering).
• Minimum 3 years in a technical environment; 5–8 years for senior profiles.
• Proven knowledge of HVAC, utilities, Black Utilities, air and industrial gases.
• Familiarity with cGMP regulations, quality and safety standards.

Responsabilités

• Coordinate and implement improvements to operational processes in Facility Management, focusing on capacity and efficiency.
• Act as system owner for critical HVAC and utility systems; oversee capacity, reliability and energy efficiency.
• Conduct root cause analyses for data deviations; support investigations and deviations.
• Contribute to defining, budgeting and planning of investment projects; coordinate project start-up teams.
• Collaborate with internal/external stakeholders and serve as spokesperson during audits.

Connaissances

Analytical thinking

Strong communication skills

Formation

Master's degree or equivalent in relevant engineering field

Description du poste

Biopharma Careers is seeking a Hard services system owner specialist in Geel, Belgium. You will be the technical hub for HVAC and utility processes within a cGMP environment, coordinating improvements and ensuring optimal capacity and reliable operation.

As system owner, you will drive investigations, support deviations, and lead project start-ups while shaping budgeted investments and cross-functional collaboration with auditors and stakeholders in a dynamic pharma setting.